Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists

• Material Type: 博士論文
• Title: Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists
• Author/Editor: Ito, Takayasu
• Author Heading: Ito, Takayasu
• Publication, Distribution, etc.: 三重大学
• Publication Date: 2016-03-25
• Publication Date (W3CDTF): 2016-03-25
• Degree grantor/type: 三重大学
• Date Granted: 2016-03-25
• Date Granted (W3CDTF): 2016-03-25
• Dissertation Number: 甲医学第1759号
• Degree Type: 博士(医学)
• Conferring No. (Dissertation): 甲医学第1759号
• Text Language Code: eng
• Alias of Author: イトウ, タカヤス; 伊藤, 貴康
• Subject Heading: Aliskiren; angiotensin II receptor antagonists; direct renin inhibitor; hemodialysis; hypertension
• Target Audience: 一般
• Note (General): application/pdf; Background: A direct renin inhibitor (DRI), aliskiren, may be effective for blood pressure (BP) control in hemodialysis patients. However, it is unclear whether aliskiren has a greater beneficial effect on BP and humoral factors than angiotensin II receptor antagonists (ARBs) in hypertensive patients on hemodialysis. Methods: Eighteen hemodialysis patients (58 ± 14 years) on the recommended dose of an ARB were prospectively randomized into two groups: ARB and DRI groups. Patients in the ARB group continued taking their previous ARB, whereas those in the DRI group switched to aliskiren (150 mg/day) for 12 weeks. Baseline measurements of BP and humoral factors such as plasma renin activity (PRA), plasma aldosterone concentration (PAC) and brain natriuretic peptide (BNP) were performed. Measurements were repeated every 4 weeks. Results: At baseline, no differences were observed in age, gender or BP between the two groups. Systolic BP was unaffected by treatment in either groups (group effect, p = 0.26; time effect, p = 0.38; group × time effect, p = 0.24). PRA decreased in DRI (p ≦ 0.02, group effect, p = 0.65; time effect, p = 0.13; group × time effect, p = 0.048), but not in ARB (p ≧ 0.94). PAC increased only in DRI (p ≦ 0.03), whereas BNP was unaffected in either group. Conclusion: Aliskiren at a dose of 150 mg/day had a similar effect on BP compared with ARBs, but significantly lowered PRA.; 本文 / Department of Internal Medicine, Kuwana East Medical Center, Kuwana, Mie, Japan; 7p
• DOI: info:doi/10.3109/10641963.2013.863323; https://doi.org/info:doi/10.3109/10641963.2013.863323
• Persistent ID (NDL): info:ndljp/pid/10981935; https://dl.ndl.go.jp/pid/10981935
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2017-11-03T04:45:49+09:00
• Date Created (W3CDTF): 2017-10-16
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10076/00017086; https://mie-u.repo.nii.ac.jp/records/11442
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-12-15 再収集